DOI QR코드

DOI QR Code

Pathway Crosstalk Analysis Based on Protein-protein Network Analysis in Ovarian Cancer

  • Pan, Xiao-Hua
  • Published : 2012.08.31

Abstract

Ovarian cancer is the fifth leading cause of cancer death in women aged 35 to 74 years. Although there are several popular hypothesis of ovarian cancer pathogenesis, the genetic mechanisms are far from being clear. Recently, systems biology approaches such as network-based methods have been successfully applied to elucidate the mechanisms of diseases. In this study, we constructed a crosstalk network among ovarian cancer related pathways by integrating protein-protein interactions and KEGG pathway information. Several significant pathways were identified to crosstalk with each other in ovarian cancer, such as the chemokine, Notch, Wnt and NOD-like receptor signaling pathways. Results from these studies will provide the groundwork for a combination therapy approach targeting multiple pathways which will likely be more effective than targeting one pathway alone.

Keywords

Ovarian cancer;protein-protein network;pathway crosstalk

References

  1. Adesina AM, Lopez-Terrada D, Wong KK, et al (2009). Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol, 40, 843-53. https://doi.org/10.1016/j.humpath.2008.10.022
  2. Axelrod JD, Matsuno K, Artavanis-Tsakonas S, Perrimon N (1996). Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science, 271, 1826-32. https://doi.org/10.1126/science.271.5257.1826
  3. Ayyanan A, Civenni G, Ciarloni L, et al (2006). Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA, 103, 3799-804. https://doi.org/10.1073/pnas.0600065103
  4. Barbieri F, Bajetto A, Florio T (2010). Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol, 426956.
  5. Berchuck A, Elbendary A, Havrilesky L, et al (1994). Pathogenesis of ovarian cancers. J Soc Gynecol Investig, 1, 181-90. https://doi.org/10.1177/107155769400100302
  6. Bowen NJ, Walker LD, Matyunina LV, et al (2009). Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics, 2, 71. https://doi.org/10.1186/1755-8794-2-71
  7. Bray SJ (2006). Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol, 7, 678-89. https://doi.org/10.1038/nrm2009
  8. Bruserud O, Kittang AO (2010). The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol, 341, 3-12. https://doi.org/10.1007/82_2010_18
  9. Bruserud O, Ryningen A, Olsnes AM, et al (2007). Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica, 92, 332-41. https://doi.org/10.3324/haematol.10148
  10. Colomiere M, Ward AC, Riley C, et al (2009). Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer, 100, 134-44. https://doi.org/10.1038/sj.bjc.6604794
  11. De Paepe B, Creus KK, De Bleecker JL (2008). Chemokines in idiopathic inflammatory myopathies. Front Biosci, 13, 2548-77. https://doi.org/10.2741/2866
  12. Francesconi M, Remondini D, Neretti N, et al (2008). Reconstructing networks of pathways via significance analysis of their intersections. BMC Bioinformatics, 9 Suppl 4, S9. https://doi.org/10.1186/1471-2105-9-S4-S9
  13. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF (2008). Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer, 18, 954-62. https://doi.org/10.1111/j.1525-1438.2007.01127.x
  14. Hayward P, Brennan K, Sanders P, et al (2005). Notch modulates Wnt signalling by associating with Armadillo/beta-catenin and regulating its transcriptional activity. Development, 132, 1819-30. https://doi.org/10.1242/dev.01724
  15. Hembruff SL, Cheng N (2009). Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther, 7, 254-67.
  16. Ideker T, Sharan R(2008). Protein networks in disease. Genome Res, 18, 644-52. https://doi.org/10.1101/gr.071852.107
  17. Keshava Prasad TS, Goel R, Kandasamy K, et al (2009). Human Protein Reference Database--2009 update. Nucleic Acids Res, 37, D767-72. https://doi.org/10.1093/nar/gkn892
  18. Li Y, Agarwal P, Rajagopalan D (2008). A global pathway crosstalk network. Bioinformatics, 24, 1442-7. https://doi.org/10.1093/bioinformatics/btn200
  19. Liu ZP, Wang Y, Zhang XS, Chen L (2010). Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Syst Biol, 4 Suppl 2: S11. https://doi.org/10.1186/1752-0509-4-S2-S11
  20. Merritt MA, Cramer DW (2011). Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark, 9, 287- 305. https://doi.org/10.3233/CBM-2011-0167
  21. Moreno CS (2010). The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol, 176, 518-27. https://doi.org/10.2353/ajpath.2010.090657
  22. Nanjundan M, Cheng KW, Zhang F, et al (2008). Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol, 2, 164-81. https://doi.org/10.1016/j.molonc.2008.05.001
  23. Obata K, Hoshiai H (2000). Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest, 50, 39-43.
  24. Oliva E, Sarrio D, Brachtel EF, et al (2006). High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol, 208, 708-13. https://doi.org/10.1002/path.1923
  25. Rose SL (2009). Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer, 19, 564-6. https://doi.org/10.1111/IGC.0b013e3181a12ed2
  26. Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N (2010). Notch 1 signaling is active in ovarian cancer. Gynecol Oncol, 117, 130-3. https://doi.org/10.1016/j.ygyno.2009.12.003
  27. Saito M, Okamoto A, Kohno T, et al (2000). Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer, 85, 160-5. https://doi.org/10.1002/(SICI)1097-0215(20000115)85:2%3C160::AID-IJC2%3E3.0.CO;2-5
  28. Shih Ie M, Davidson B (2009). Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol, 5, 1641-57. https://doi.org/10.2217/fon.09.126
  29. Shih Ie M, Kurman RJ (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164, 1511-8. https://doi.org/10.1016/S0002-9440(10)63708-X
  30. Sieben NL, Macropoulos P, Roemen GM, et al (2004). In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol, 202, 336-40. https://doi.org/10.1002/path.1521
  31. Singer G, Kurman RJ, Chang HW, et al (2002). Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol, 160, 1223-8. https://doi.org/10.1016/S0002-9440(10)62549-7
  32. Singer G, Oldt R, 3rd, Cohen Y, et al (2003). Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst, 95, 484-6. https://doi.org/10.1093/jnci/95.6.484
  33. Singer G, Stohr R, Cope L, et al (2005). Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol, 29, 218-24. https://doi.org/10.1097/01.pas.0000146025.91953.8d
  34. Stark C, Breitkreutz BJ, Chatr-Aryamontri A, et al (2011). The BioGRID Interaction Database: 2011 update. Nucleic Acids Res, 39, D698-704. https://doi.org/10.1093/nar/gkq1116
  35. Team RDC (2011). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
  36. Torpy JM, Burke AE, Golub RM (2011). JAMA patient page. Ovarian cancer. JAMA, 305, 2484. https://doi.org/10.1001/jama.305.23.2484
  37. Turashvili G, Bouchal J, Baumforth K, et al (2007). Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. Bmc Cancer, 7, 55. https://doi.org/10.1186/1471-2407-7-55
  38. Van Es JH, Jay P, Gregorieff A, et al (2005). Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat Cell Biol, 7(4): 381-386. https://doi.org/10.1038/ncb1240
  39. Wang Z, Li Y, Kong D, et al (2010). Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett, 292, 141-8. https://doi.org/10.1016/j.canlet.2009.11.012
  40. Zabel BA, Zuniga L, Ohyama T, et al (2006). Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol, 34, 1021-32. https://doi.org/10.1016/j.exphem.2006.05.003
  41. Zhao XM, Wang RS, Chen L, Aihara K (2008). Uncovering signal transduction networks from high-throughput data by integer linear programming. Nucleic Acids Res, 36, e48. https://doi.org/10.1093/nar/gkn145

Cited by

  1. Construction of a Protein-Protein Interaction Network for Chronic Myelocytic Leukemia and Pathway Prediction of Molecular Complexes vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5325
  2. Shortest Path Analyses in the Protein-Protein Interaction Network of NGAL (Neutrophil Gelatinase-associated Lipocalin) Overexpression in Esophageal Squamous Cell Carcinoma vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6899
  3. Protein-protein Interaction Network Analyses for Elucidating the Roles of LOXL2-delta72 in Esophageal Squamous Cell Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2345
  4. NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis vol.13, pp.1, 2015, https://doi.org/10.3892/mmr.2015.4556
  5. pathway is associated with Advanced Ovarian Cancer in Saudi Patients vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5807
  6. Integrative Meta-Analysis of Multiple Gene Expression Profiles in Acquired Gemcitabine-Resistant Cancer Cell Lines to Identify Novel Therapeutic Biomarkers vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2793
  7. A Hybrid of Metabolic Flux Analysis and Bayesian Factor Modeling for Multiomic Temporal Pathway Activation vol.4, pp.8, 2015, https://doi.org/10.1021/sb5003407
  8. Multiple Testing of Submatrices of a Precision Matrix With Applications to Identification of Between Pathway Interactions pp.1537-274X, 2016, https://doi.org/10.1080/01621459.2016.1251930